Search

Turning thoughts into reality

Turning thoughts into reality
By Dr Adi Zoref (@ZorefAdi)

I am an Israeli physician, trained in internal medicine. During my residency rotation in hematology at Meir Medical Center, I met a patient who changed my life.

Read more

Meet Shaun McCann, our July volunteer of the month

Can you tell us what you do for EHA and when you started?
I have been a member of the EHA since its beginning. I began taking part in tutorials in 2007.

Read more

Meet Shaun McCann, our July volunteer of the month

Can you tell us what you do for EHA and when you started?
I have been a member of the EHA since its beginning. I began taking part in tutorials in 2007.

Read more

EHA Guidelines on Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults

Chronic myelomonocytic leukemia (CMML) is a disease of the elderly, and by far the most frequent overlap myelodysplastic/myeloproliferative neoplasm in adults.

Read more

Meet Michaela Gruber, our December volunteer of the month

Can you tell us what you do for EHA and when you started?
Over six years ago, I was one of the initiators of what is now the “YoungEHA” and the “Young-EHA Committee”.

Read more

Meet Michaela Gruber, our December volunteer of the month

Can you tell us what you do for EHA and when you started?
Over six years ago, I was one of the initiators of what is now the “YoungEHA” and the “Young-EHA Committee”.

Read more

Meet Shai Izraeli, our volunteer of the month

Can you tell us what you do for EHA and when you started?
I am currently the EHA Treasurer, a member of the Executive Board, and the incoming Chair of the Research Committee.

Read more

Meet Shai Izraeli, our volunteer of the month

Can you tell us what you do for EHA and when you started?
I am currently the EHA Treasurer, a member of the Executive Board, and the incoming Chair of the Research Committee.

Read more

Does the patient with myelofibrosis feel better through Pacritinib?

Pacritinib is an oral next-generation multikinase inhibitor with specificity for JAK2 and FLT3 being evaluated to treat myelofibrosis in two Phase 3 trials.

Read more